NCT04247594 - Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

June 8, 2021

Study Completion Date

June 8, 2021

Conditions

Sickle Cell Disease

Interventions

DRUG

Voxelotor

synthetic small molecule supplied as 500 mg tablets

Trial Locations (6)

Guy's and St Thomas' NHS Foundation Trust, London

Guy's Hospital, London

Hammersmith Hospital, London

Homerton University, London

King's College Hospital, London

Royal London Hospital, Barts Health NHS Trust, London